Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia

The place of long-acting injectable antipsychotics in the treatment of schizophrenia

“…Claims data in the United States show that LAIs are most often used in reaction to relapse, rather than proactively to prevent them. 29 Why should we wait until someone relapses to use an appropriate relapse prevention strategy? Answering this question requires an appreciation of benefits and risks of LAIs.…”